Le fibrosarcome infantile (IFS) est défini par fusion ETV6-NTRK3 (>90%). Larotrectinib a une...
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | BMA-NTRK-FUSION-IFS |
|---|---|
| Type | Pertinence thérapeutique |
| État | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Maladies | DIS-IFS |
| Sources | SRC-CIVIC SRC-FDA-CDS-2026 |
Faits relatifs à l ' action en justice
| Biomarqueur | BIO-NTRK-FUSION |
|---|---|
| Variante | Fusion ETV6-NTRK3 (lésion définitive) |
| Maladie | DIS-IFS |
| Niveau ESCAT | IA |
| Combinaisons recommandées | larotrectinib monotherapy (1L for unresectable / metastatic IFS — chemotherapy-sparing), entrectinib monotherapy |
| Contre-indiqué en monothérapie | VAC chemotherapy (vincristine/actinomycin/cyclophosphamide) as 1L when NTRK-TKI available — no longer standard given larotrectinib tolerability and efficacy |
| Résumé des faits | Infantile fibrosarcoma (IFS) is defined by ETV6-NTRK3 fusion (>90%). Larotrectinib has transformative activity (SCOUT pediatric trial, Laetsch Lancet Oncol 2018 — ORR 93% in IFS), enabling organ-sparing surgery and avoiding mutilating resection or intensive chemotherapy. Tumor-agnostic FDA approval since 2018; SCOUT data drove pediatric label. |
Notes
ESCAT IA. OncoKB Level 1. IFS is the prototype tumor for the paradigm shift from cytotoxic to targeted therapy in pediatric oncology. Prior standard (VAC chemotherapy) achieved ~70% response but with substantial toxicity. Larotrectinib enables less mutilating surgery in localized IFS. Source-gap: SRC-NCCN-PEDIATRIC-SARCOMA / SRC-SCOUT not yet ingested.
Utilisé par
No reverse references found in the YAML corpus.